Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: A phase II study

Lance C. Pagliaro, Dallas L. Williams, Danai Daliani, Michael B. Williams, William Osai, Michael Kincaid, Sijin Wen, Peter F. Thall, Curtis A. Pettaway

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

Purpose: Men with penile squamous cell carcinoma and regional lymph node involvement have a low probability of survival with lymphadenectomy alone. A multimodal approach to treatment is desirable for such patients. We performed a phase II study of neoadjuvant chemotherapy with the objective of determining the response rate, time to progression (TTP), and overall survival (OS) among patients with bulky adenopathy. Patients and Methods: Eligible patients had stage N2 or N3 (stage III or stage IV) penile cancer without distant metastases. Neoadjuvant treatment (four courses every 3-4 weeks) consisted of paclitaxel 175 mg/m2 administered over 3 hours on day 1; ifosfamide 1,200 mg/m2 on days 1 to 3; and cisplatin 25 mg/m2 on days 1 to 3. Clinical and pathologic responses were assessed, and patient groups were compared for TTP and OS. Results: Thirty men received chemotherapy of whom 15 (50.0%) had an objective response and 22 (73.3%) subsequently underwent surgery. Three patients had no remaining tumor on histopathology. Nine patients (30.0%) remained alive and free of recurrence (median follow-up, 34 months; range, 14-59 months), and two patients died of other causes without recurrence. Improved TTP and OS were significantly associated with a response to chemotherapy (P < .001 and P = .001, respectively), absence of bilateral residual tumor (P = .002 and P = .017, respectively), and absence of extranodal extension (P = .001 and P = .004, respectively) or skin involvement (P = .009 and P = .012, respectively). Conclusion: The neoadjuvant regimen of paclitaxel, ifosfamide, and cisplatin induced clinically meaningful responses in patients with bulky regional lymph node metastases from penile cancer.

Original languageEnglish (US)
Pages (from-to)3851-3857
Number of pages7
JournalJournal of Clinical Oncology
Volume28
Issue number24
DOIs
StatePublished - Aug 20 2010
Externally publishedYes

Fingerprint

Penile Neoplasms
Ifosfamide
Drug Therapy
Survival
Lymph Nodes
Neoplasm Metastasis
TP protocol
Recurrence
Neoadjuvant Therapy
Residual Neoplasm
Paclitaxel
Lymph Node Excision
Cisplatin
Squamous Cell Carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pagliaro, L. C., Williams, D. L., Daliani, D., Williams, M. B., Osai, W., Kincaid, M., ... Pettaway, C. A. (2010). Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: A phase II study. Journal of Clinical Oncology, 28(24), 3851-3857. https://doi.org/10.1200/JCO.2010.29.5477

Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer : A phase II study. / Pagliaro, Lance C.; Williams, Dallas L.; Daliani, Danai; Williams, Michael B.; Osai, William; Kincaid, Michael; Wen, Sijin; Thall, Peter F.; Pettaway, Curtis A.

In: Journal of Clinical Oncology, Vol. 28, No. 24, 20.08.2010, p. 3851-3857.

Research output: Contribution to journalArticle

Pagliaro, LC, Williams, DL, Daliani, D, Williams, MB, Osai, W, Kincaid, M, Wen, S, Thall, PF & Pettaway, CA 2010, 'Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: A phase II study', Journal of Clinical Oncology, vol. 28, no. 24, pp. 3851-3857. https://doi.org/10.1200/JCO.2010.29.5477
Pagliaro, Lance C. ; Williams, Dallas L. ; Daliani, Danai ; Williams, Michael B. ; Osai, William ; Kincaid, Michael ; Wen, Sijin ; Thall, Peter F. ; Pettaway, Curtis A. / Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer : A phase II study. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 24. pp. 3851-3857.
@article{a0c2615b39d64e9fbae456fb001623b4,
title = "Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: A phase II study",
abstract = "Purpose: Men with penile squamous cell carcinoma and regional lymph node involvement have a low probability of survival with lymphadenectomy alone. A multimodal approach to treatment is desirable for such patients. We performed a phase II study of neoadjuvant chemotherapy with the objective of determining the response rate, time to progression (TTP), and overall survival (OS) among patients with bulky adenopathy. Patients and Methods: Eligible patients had stage N2 or N3 (stage III or stage IV) penile cancer without distant metastases. Neoadjuvant treatment (four courses every 3-4 weeks) consisted of paclitaxel 175 mg/m2 administered over 3 hours on day 1; ifosfamide 1,200 mg/m2 on days 1 to 3; and cisplatin 25 mg/m2 on days 1 to 3. Clinical and pathologic responses were assessed, and patient groups were compared for TTP and OS. Results: Thirty men received chemotherapy of whom 15 (50.0{\%}) had an objective response and 22 (73.3{\%}) subsequently underwent surgery. Three patients had no remaining tumor on histopathology. Nine patients (30.0{\%}) remained alive and free of recurrence (median follow-up, 34 months; range, 14-59 months), and two patients died of other causes without recurrence. Improved TTP and OS were significantly associated with a response to chemotherapy (P < .001 and P = .001, respectively), absence of bilateral residual tumor (P = .002 and P = .017, respectively), and absence of extranodal extension (P = .001 and P = .004, respectively) or skin involvement (P = .009 and P = .012, respectively). Conclusion: The neoadjuvant regimen of paclitaxel, ifosfamide, and cisplatin induced clinically meaningful responses in patients with bulky regional lymph node metastases from penile cancer.",
author = "Pagliaro, {Lance C.} and Williams, {Dallas L.} and Danai Daliani and Williams, {Michael B.} and William Osai and Michael Kincaid and Sijin Wen and Thall, {Peter F.} and Pettaway, {Curtis A.}",
year = "2010",
month = "8",
day = "20",
doi = "10.1200/JCO.2010.29.5477",
language = "English (US)",
volume = "28",
pages = "3851--3857",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "24",

}

TY - JOUR

T1 - Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer

T2 - A phase II study

AU - Pagliaro, Lance C.

AU - Williams, Dallas L.

AU - Daliani, Danai

AU - Williams, Michael B.

AU - Osai, William

AU - Kincaid, Michael

AU - Wen, Sijin

AU - Thall, Peter F.

AU - Pettaway, Curtis A.

PY - 2010/8/20

Y1 - 2010/8/20

N2 - Purpose: Men with penile squamous cell carcinoma and regional lymph node involvement have a low probability of survival with lymphadenectomy alone. A multimodal approach to treatment is desirable for such patients. We performed a phase II study of neoadjuvant chemotherapy with the objective of determining the response rate, time to progression (TTP), and overall survival (OS) among patients with bulky adenopathy. Patients and Methods: Eligible patients had stage N2 or N3 (stage III or stage IV) penile cancer without distant metastases. Neoadjuvant treatment (four courses every 3-4 weeks) consisted of paclitaxel 175 mg/m2 administered over 3 hours on day 1; ifosfamide 1,200 mg/m2 on days 1 to 3; and cisplatin 25 mg/m2 on days 1 to 3. Clinical and pathologic responses were assessed, and patient groups were compared for TTP and OS. Results: Thirty men received chemotherapy of whom 15 (50.0%) had an objective response and 22 (73.3%) subsequently underwent surgery. Three patients had no remaining tumor on histopathology. Nine patients (30.0%) remained alive and free of recurrence (median follow-up, 34 months; range, 14-59 months), and two patients died of other causes without recurrence. Improved TTP and OS were significantly associated with a response to chemotherapy (P < .001 and P = .001, respectively), absence of bilateral residual tumor (P = .002 and P = .017, respectively), and absence of extranodal extension (P = .001 and P = .004, respectively) or skin involvement (P = .009 and P = .012, respectively). Conclusion: The neoadjuvant regimen of paclitaxel, ifosfamide, and cisplatin induced clinically meaningful responses in patients with bulky regional lymph node metastases from penile cancer.

AB - Purpose: Men with penile squamous cell carcinoma and regional lymph node involvement have a low probability of survival with lymphadenectomy alone. A multimodal approach to treatment is desirable for such patients. We performed a phase II study of neoadjuvant chemotherapy with the objective of determining the response rate, time to progression (TTP), and overall survival (OS) among patients with bulky adenopathy. Patients and Methods: Eligible patients had stage N2 or N3 (stage III or stage IV) penile cancer without distant metastases. Neoadjuvant treatment (four courses every 3-4 weeks) consisted of paclitaxel 175 mg/m2 administered over 3 hours on day 1; ifosfamide 1,200 mg/m2 on days 1 to 3; and cisplatin 25 mg/m2 on days 1 to 3. Clinical and pathologic responses were assessed, and patient groups were compared for TTP and OS. Results: Thirty men received chemotherapy of whom 15 (50.0%) had an objective response and 22 (73.3%) subsequently underwent surgery. Three patients had no remaining tumor on histopathology. Nine patients (30.0%) remained alive and free of recurrence (median follow-up, 34 months; range, 14-59 months), and two patients died of other causes without recurrence. Improved TTP and OS were significantly associated with a response to chemotherapy (P < .001 and P = .001, respectively), absence of bilateral residual tumor (P = .002 and P = .017, respectively), and absence of extranodal extension (P = .001 and P = .004, respectively) or skin involvement (P = .009 and P = .012, respectively). Conclusion: The neoadjuvant regimen of paclitaxel, ifosfamide, and cisplatin induced clinically meaningful responses in patients with bulky regional lymph node metastases from penile cancer.

UR - http://www.scopus.com/inward/record.url?scp=77956233851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956233851&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.29.5477

DO - 10.1200/JCO.2010.29.5477

M3 - Article

C2 - 20625118

AN - SCOPUS:77956233851

VL - 28

SP - 3851

EP - 3857

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 24

ER -